Cardiology

Labeling for triptan medications warns of potential for ischemic events but is the concern theoretical or real? A new study tests the association.

The 10 take-home points from the ACC/AHA cover diet, exercise, cardiac rehab, use of new treatments, reliance on statins, guidance on beta-blockers, plus more.

Your daily dose of the clinical news you may have missed.

ACC.24: Even modest alcohol intake increases risk for coronary heart disease in men and women but women are at much greater risk across levels of weekly consumption.

ACC.24: Adults with a history of CVD consumed more than double the recommended daily sodium amount, reported researchers.

Your daily dose of the clinical news you may have missed.

The web app showed more than 90% concordance with clinical assessment of eligibility for low dose rosuvastatin; study yields 35.5% reduction in LDL-C.

ACC.24: Results of STEP HFpEF DM showed significant improvement in quality of life measures among adults with obesity-related HFpEF and type 2 diabetes.

ACC.24: Zilebesiran led to clinically and statistically significant reductions in SBP on top of either a diuretic, CCB, or ARB; SQ dosing is every 3-6 months.

ACC.24: Individuals with ASCVD not at target LDL-C on maximum statin therapy need immediate intervention and one that works, said V-INITIATE primary investigator.

ACC.24: Michael Koren, MD, highlights how the nonstatin lipid-lowering medication's mechanism of action against PCSK9 differs from others in the category.

ACC.24: The primary investigator of the VICTORION-INITIATE study explains why new strategies are needed to accelerate LDL-C lowering in high-risk individuals.

ACC. 24: A structured, systematic approach to lipid-lowering therapy in secondary prevention is needed to ensure targets are met and met swiftly, said researchers.

Your daily dose of the clinical news you may have missed.

In a population cohort of adults with T2D, a BMI above "normal" range appeared more likely to protect against CV death in those older than age 65 years than those younger.

Your daily dose of the clinical news you may have missed.

Migraine was the most important nontraditional risk factor linked to stroke in adults aged 18 to 34 years and should be considered in evaluation for an event.

Your daily dose of the clinical news you may have missed.

ACC.24: Data showed that individuals who used e-cigarettes were approximately 19% more likely to develop heart failure compared with those who had never vaped.

ACC.2024: Two abstracts presented during the ACC Scientific Sessions indicate cardiologists are very hesitant to prescribe medical therapy for obesity.

Your daily dose of the clinical news you may have missed.

ACC.24: Loss of estrogen's cardioprotective effect could account for the 2-fold greater increase in CAC score seen among postmenopausal women compared with men.

ACC.24: Data showed that participants with ADHD who were prescribed stimulants were 17% more likely to develop cardiomyopathy at 1 year.

Your daily dose of the clinical news you may have missed.

ACC.24: Icosapent ethyl was associated with reduced rate of MACE at all baseline levels of Lp(a) in participants with elevated TG and at high risk for CVD.

Your daily dose of the clinical news you may have missed.

Longer duration of remission was associated with a greater reduction in CKD and CVD risk, according to a post hoc analysis of the Look AHEAD study.

Your daily dose of the clinical news you may have missed.

ACC.24: Data from an analysis of the CLEAR Outcomes trial showed bempedoic acid was well-tolerated and reduced CV events in Hispanic/Latinx and non-Hispanic/Latinx participants.

CLEAR Outcomes PI Steven Nissen, MD, links findings from the pivotal trial with labeling updates that make bempedoic acid the only nonstatin agent approved to reduce CV risk.